ClinicalTrials.gg
RecruitingNCT06270667LYMfitUpdated Mar 22, 2024

Effects of Exercise Training in Survivors of Lymphoma

An interventional study of Aerobic Exercise and Combined Aerobic and Resistance Exercise in Lymphoma, Physical Exercise and Cardiotoxicity, sponsored by Norwegian School of Sport Sciences. Recruiting at 2 sites in 2 countries. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Norwegian School of Sport Sciences · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Lymphoma with a site in Norway — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Norway.

Planned enrollment
9th of 19
280 · median 200
Started
2024
with 3 others
No phase
6 of 20
2 open now
Registered
18th of 20
by date

Among the 20 studies in Lymphoma with a site in Norway, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 with no phase, and was the 18th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 20 studies in Lymphoma with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lymphoma with a site in Norway, or all of them as a file.
02

Study summary

This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

Read the detailed description

In this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. Therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. Participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. This study recruits through invitation only.

The primary endpoint in this study is the change in cardiorespiratory fitness, assessed as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.

03

Conditions studied

  • Lymphoma
  • Physical Exercise
  • Cardiotoxicity
  • Cardiovascular Diseases
  • Chemotherapeutic Toxicity
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Listed in relevant registers
  • Confirmed lymphoma diagnosis (i.e., Hodgkin lymphoma and aggressive non-Hodgkin lymphoma)
  • Completed treatment in the past two to five years without relapse or second cancer
  • Previous anthracycline treatment with or without mediastinal radiation
  • No severe cancer-related fatigue (per self-report)

Inclusion Criteria Lymphoma participants and non-cancer reference group:

  • Currently not performing >75 minutes/week of aerobic exercise
  • Willing and able to adhere to all study procedures.

Exclusion criteria

Exclusion Criteria Lymphoma participants:

  • Relapse since diagnosis
  • A history, or current presence, of another diagnosis of invasive cancer of any kind

Exclusion Criteria Lymphoma participants and non-cancer reference group:

  • Presence of any uncontrolled- or recent cardiovascular disease
  • Has undergone heart surgery
  • Uses a pacemaker
  • Pregnancy
  • Unable to read and understand Swedish (applicable for the Swedish site only)
  • Unable to read and understand Norwegian (applicable for the Norwegian site)
  • Any physical or mental health condition restricting adherence to study protocol
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Aerobic Exercise

    Aerobic Exercise twice weekly for 5 months.

    Behavioral: Aerobic Exercise

  • Experimental
    Combined Aerobic and Resistance Exercise

    Combined Aerobic and Resistance Exercise twice weekly for 5 months.

    Behavioral: Combined Aerobic and Resistance Exercise

  • No intervention
    Standard Care

    Standard Care, i.e no exercise intervention.

  • Active comparator
    Reference Aerobic Exercise

    Aerobic Exercise twice weekly for 5 months.

    Behavioral: Aerobic Exercise

Interventions

  • BehavioralAerobic Exercise

    Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)

  • BehavioralCombined Aerobic and Resistance Exercise

    Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.

06

What researchers measure

Primary outcomes

  1. VO2peak

    Peak oxygen uptake during a treadmill-based cardiopulmonary exercise test

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

Secondary outcomes

  1. Systolic- and diastolic heart chamber dimensions

    Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  2. Systolic- and diastolic longitudinal strain

    Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  3. Lean body mass

    Body composition will be assessed by dual x-ray absorptiometry

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  4. Fat mass

    Body composition will be assessed by dual x-ray absorptiometry

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  5. Forced Vital Capacity

    Lung function are assessed with spirometry.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  6. Forced Expiratory Volume 1 sec

    Lung function are assessed with spirometry.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  7. Maximal voluntary ventilation

    Lung function are assessed with spirometry.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  8. Diffusion capacity

    Diffusion capacity for carbon monoxide is assessed with single breath diffusion capacity test.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  9. Physical activity

    Actigraph accelerometer with physical activity diary. 7 days consecutive measurement at each timepoints.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  10. Physical activity

    Patient reported physical activity is assessed with Godin Leisure-Time Exercise Questionnaire

    Time frame: Baseline, 10-12 weeks from baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  11. Global Health related Quality of life

    Patient reported health related quality of life will be assessed with EORTC QLQ C 30

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  12. Blood volume

    Will be assessed in Norway only. Using the carbon monoxide rebreathing method.

    Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline

  13. Muscle fiber area

    Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry

    Time frame: Baseline, five months from baseline (i.e. end of intervention)

  14. Muscle fiber type

    Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry

    Time frame: Baseline, five months from baseline (i.e. end of intervention)

  15. Muscle mitochondria mass

    Will be assessed in Norway only. Change in mitochondrial proteins will be assessed in muscle biopsies using western blot

    Time frame: Baseline, five months from baseline (i.e. end of intervention)

Other outcomes

  1. Muscle genome-wide DNA methylation and gene expression

    Will be assessed in Norway only. For a sub-group of participants, muscle biopsies will be further processed for RNA and DNA

    Time frame: Baseline, five months from baseline (i.e. end of intervention)

  2. Adverse events

    Medical records and Patient reported outcome version of the Common Terminology Criteria for Adverse Events.

    Time frame: Five months from baseline (i.e. end of intervention)

07

Study locations

1 of 2 sites recruiting
  • Norweigan School of Sport Sciences
    Oslo, Norway
    Not yet recruiting
    • Tormod S. Nilsen, PhD · Contact
  • Helena Igelström
    Uppsala, Sweden
    Recruiting
    • Helena Igelström, PhD · Contact
    • Anna Henriksson, PhD · Contactanna.km.henriksson@uu.se · 709394175
    • Helena Igelström, PhD · Principal investigator
    • Anna Henriksson, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2028, 53 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 53 months is above that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Feb 21, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06270667
Lead sponsor
Norwegian School of Sport Sciences
Collaborators
Uppsala University
Responsible party
Tormod Skogstad Nilsen (Principal Investigator, PhD, Norwegian School of Sport Sciences) — Principal investigator
First posted
Feb 21, 2024
Start date
Mar 20, 2024
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Mar 22, 2024

Study contacts

Tormod S. Nilsen, PhD
Contact
tormodsn@nih.no
95069857 ext. 0047
Helena Igelström, PhD
Contact
helena.igelstrom@neuro.uu.se
729999599 ext. 0046
Tormod S. Nilsen, PhD
principal investigator · Norwegian School of Sport Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion